Topical formulations comprising a steroid

ABSTRACT

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

INTRODUCTION

Aspects of the present application provide pharmaceutical topicalsprayable compositions comprising at least one steroid as an activeagent. The present application also provides compositions that areuseful in the prophylaxis, amelioration or treatment of skin diseases ordisorders, such as psoriasis, steroid responsive dermatoses, andassociated diseases or disorders. The present application furtherprovides processes for preparing the compositions and methods ofadministration of the compositions onto the skin, in the form of sprays.

Psoriasis, a chronic, idiopathic, genetically determined, andenvironmentally influenced disorder has been treated empirically forcenturies with varied success. Its association with arthropathy and itssignificant psychological consequences have necessitated a comprehensiveteam approach for optimal care. Psoriasis is a non-contagious autoimmunedisease which affects the skin and joints. It commonly causes red scalypatches to appear on the skin. The scaly patches caused by psoriasis,called psoriatic plaques, are areas of inflammation and excessive skinproduction. Skin rapidly accumulates at these sites and takes on asilvery-white appearance. Plaques frequently occur on the skin of theelbows and knees, but can affect any area including the scalp andgenitals. In contrast to eczema, psoriasis is more likely to be found onthe extensor aspect of the joint. The disorder is a chronic recurringcondition which varies in severity from minor localized patches tocomplete body coverage. Fingernails and toenails are frequently affected(psoriatic nail dystrophy) and can be seen as an isolated finding.Psoriasis can also cause inflammation of the joints, which is known aspsoriatic arthritis. Ten to fifteen percent of people with psoriasishave psoriatic arthritis. The cause of psoriasis is not known, but it isbelieved to have a genetic component. There are many treatmentsavailable, but because of its chronic recurrent nature psoriasis is achallenge to treat.

At present, corticosteroids are being increasingly used in the therapyof psoriasis. The corticosteroids are a class of compounds comprisingsteroids (lipids that contain a hydrogenatedcyclopentoperhydrophenanthrene ring system) elaborated by the adrenalcortex (except sex hormones of adrenal origin) in response to therelease of adrenocorticotrophin or adrenocorticotropic hormone by thepituitary gland, or to any synthetic equivalent, or to angiotensin II.In pharmacologic doses, corticosteroids are used primarily for theiranti-inflammatory and/or immunosuppressive effects.

Various other therapies are also being used in treatment of psoriasis.Keratolytic agents, applied topically, provide adjunctive aid in helpingto control stable hyperkeratotic forms of psoriasis. Ointment and creamscontaining coal tar, dithranol (anthralin), vitamin D₃ analogues (forexample, calcipotriol), and retinoids are routinely used. Some of thesystemic chemotherapeutic options have been used to help control severeforms of psoriasis. The three main traditional systemic treatments aremethotrexate, cyclosporine and retinoids. Methotrexate and cyclosporineare immunosupressant drugs; retinoids are synthetic forms of vitamin A.Other drugs, found to be effective in psoriasis, include theantimetabolite tioguanine, the cytotoxic agent hydroxyurea,sulfasalazine, the immunosupressants mycophenolate mofetil, azathioprineand oral tacrolimus. In 2008, three new treatment options were approvedin the U.S. for treating psoriasis: 1) Taclonex® Scalp, a topicalointment for treating scalp psoriasis; 2) the Xtrac® Velocity excimerlaser system, which emits a high-intensity beam of ultraviolet light andcan treat moderate to severe psoriasis; and 3) the biologic drugadalimumab (brand name Humira®) for treating moderate to severepsoriasis.

Topical corticosteroids, such as betamethasone dipropionate, areeffective in treatment of corticosteroid-responsive dermatoses primarilybecause of their anti-inflammatory, antipruritic and vasoconstrictiveactions. Betamethasone dipropionate is an analog of prednisolone, andhas a high degree of corticosteroid activity and a slight degree ofmineralocorticoid activity. Betamethasone dipropionate is of particularvalue when used in short courses for the treatment of more resistantdermatoses such as psoriasis (excluding widespread plaque psoriasis),atopic dermatitis, and other skin conditions that do not respondsatisfactorily to less active steroids.

The drug compound having the adopted name “betamethasone dipropionate”has a chemical name9-fluoro-11(β),17,21-trihydroxy-16(β)-methylpregna-1,4-diene-3,20-dione17,21-dipropionate and is represented by structural Formula I.

Betamethasone dipropionate is a white to cream white, crystallinepowder. It is practically insoluble in water, sparingly soluble inethanol and freely soluble in acetone and chloroform.

Topical betamethasone dosage forms, such as aerosol foam, cream,ointment, gel, and lotion formulations are commercially available.Combination formulations of the betamethasone dipropionate withcalcipotriene hydrate and also with clotrimazole exist. Betamethasonedipropionate is the active ingredient in commercially available productssold as DIPROLENE AF® and DIPROLENE® that comprise 0.05% betamethasonebase, intended for application to affected skin areas once or twicedaily.

U.S. Pat. Nos. 6,126,920 and 7,078,058 disclose betamethasone valerateaerosols with a quick-break foaming agent, a propellant, and a bufferingagent, wherein ethanol is present. U.S. Pat. No. 5,369,131 discloses aliquid mechanically foamable pharmaceutical composition, which ispropellant free, for local application. U.S. Patent ApplicationPublication No. 2008/0102039 discloses spray foaming dosage compositionscomprising propylene glycol. U.S. Pat. No. 5,958,379 discloses apharmaceutical composition that is sprayable as liquid droplets, forminga preparation within times less than 4 seconds. U.S. Patent ApplicationPublication No. 2006/0239929 discloses a sprayable composition for thetreatment of psoriasis, comprising clobetasol as the active agenttogether with ethyl alcohol.

U.S. Patent Application Publication No. 2009/0098069 discloses analcohol-free composition comprising a physiologically active agent, oneor more dermal penetration enhancers, selected from the group consistingof ethers of diethylene glycol and ester sunscreens, and one or morenon-volatile liquid's in an alcohol-free composition.

U.S. Patent Application Publication No. 2008/0300229 claims apharmaceutical/dermatological composition comprising a corticoidsolubilized in a vehicle comprising an oily phase, comprising one ormore oils, with no vitamin D derivative. A corticoid can be clobetasolpropionate.

U.S. Patent Application Publication No. 2008/0206155 discloses anon-alcoholic foaming pharmaceutical emulsion composition, comprising aneffective amount of a steroid (hydrocortisone, hydrocortisone acetate,desonide, betamethasone valerate, etc.) as an active pharmaceuticalagent having a degree of solubility in the emulsion composition, anunctuous emollient, and at least one liquefied or compressed gaspropellant, being packaged in an aerosol container.

Corticosteroids in the forms of alcohol solutions, lotions, creams, andointments are conventionally used for the treatment of skin diseases inhumans, such as, for example, eczema, infantile eczema, atopicdermatitis, dermatitis herpetiformis, contact dermatitis, seborrheicdermatitis, neurodermatitis, psoriasis, and intertrigo. Manyformulations containing such active substances are greasy, and hence areunpleasant to apply on large areas of the skin. Ineffectiveness oflotion, cream, and ointment formulations is observed, since they aregenerally too viscous to allow efficient penetration of the active agentin the epidermis, and a solution composition has a tendency to evaporatebefore the active agent penetrates the epidermis. In addition, someconventional cream and ointment bases are irritating to the skin,particularly over the long exposure that is frequently required forefficacy, and the fluidity of lotions often makes the physicalapplication difficult to control over a desired area. Moreover, it isnecessary to rub such formulations into the target site to improve thepenetration of the active agent into the epidermis, an action whichitself produces irritation. The formulations containing ethanol sufferthe well known adverse effects of ethanol, i.e., irritation. Furthermany formulations contain propylene glycol, which is an excellentvehicle and solvent for preparation of dermatologic dosage forms;however, since propylene glycol has a tendency to induce irritant orallergic skin reactions, such formulations do not promote patientcompliance. Additionally, pressurized aerosol (propellant based)formulations in the market have the disadvantage of relatively highcost, primarily due to the construction of the containers and meteringvalves. Also, the propellant based formulations have undesirableenvironmental impact.

Another disadvantage of conventional formulations is that their activeagents act for a short duration of time and thus require frequentre-application, thereby providing a negative impact on treatmentcompliance and quality of life of the patient. Furthermore, severalsteroidal formulations are available that cause substantial foamformation upon spraying onto the skin, which is highly undesirable to apatient using such preparations for aesthetic reasons. Several topicalformulations available commercially are primarily incapable of providingthe much needed soothing effect to the affected areas, particularly inconditions such as psoriasis. The disadvantages of topical agents vary,in that they can often irritate normal skin, be time consuming andawkward to apply, cannot be used for long periods, can stain clothing,and/or have an objectionable odour. As a result, it is sometimesdifficult for people to maintain regular applications of thesemedications. Abrupt withdrawal of some topical agents, particularlycorticosteroids, can cause an aggressive recurrence of the condition.This is known as “rebound” of the condition.

There remains, therefore, an unmet need for improved patient complianttopical formulations that are effective in the treatment of skindisorders such as psoriasis, and which provide improved delivery of theactive agent at the desired site of action, with decreased inconvenienceand irritation, increased ease of use for the patient, and longerduration of action.

SUMMARY

Aspects of the present application provide sprayable pharmaceuticaltopical compositions comprising at least one steroid as an active agent.

In aspects, the present application provides pharmaceutical topicalspray compositions comprising at least one steroid as an active agentand being propellant-free and/or substantially non-foaming.

Aspects of the present application provide processes for preparingpropellant-free topical spray compositions.

Aspects of the present application provide methods of usingpropellant-free topical spray compositions comprising at least onesteroid as an active agent. In embodiments, methods of using compriseadministering a pharmaceutically effective amount of a spray compositiondirectly onto an affected part of the skin of a subject in need thereof.

In aspects, the present application provides uses of propellant-freetopical spray compositions comprising at least one steroid as an activeagent for prophylaxis, amelioration, or treatment of psoriasis, steroidresponsive dermatoses, erythema, contact sensitivity reactions, andother associated diseases or disorders.

In embodiments, compositions of the present application are aqueousbased emulsion sprays.

Aspects of the application provide propellant-free sprayable topicalpharmaceutical compositions, comprising an active agent, an emulsifyingagent, a polymer, water, a water-immiscible substance, and an activeagent skin penetration enhancer in amounts about 0.001-15 percent byweight.

Aspects of the application provide propellant-free sprayable topicalpharmaceutical compositions comprising a betamethasone compound, inamounts equivalent to about 0.025 to about 0.1 percent by weight ofbetamethasone base, an emulsifying agent, a polymer, water, awater-immiscible substance, and an active agent skin penetrationenhancer in amounts about 3 to about 10 percent by weight.

Aspects of the application provide processes for preparing apropellant-free pharmaceutical topical sprayable composition,comprising:

a) heating a mixture comprising an emulsifying agent and awater-immiscible substance to obtain an oily phase;

b) optionally, mixing an antioxidant, preservative, or both with theoily phase of a);

c) mixing an active agent with a penetration enhancer;

d) mixing the material of c) with the mixture of a) or b);

e) dissolving a polymer in water; and

f) mixing the oily phase of d) with an aqueous phase of e), to form anemulsion.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows comparative in vitro dissolution profiles of drug releasedfrom formulations prepared in Example 1, and a commercially availablereference product.

FIG. 2 shows the concentrations of drug in different skin layers at 8hours and 24 hours after application, for certain formulations preparedin Examples 2 and 3.

FIG. 3 shows structural formulas for certain betamethasonedipropionate-related impurities.

DETAILED DESCRIPTION

The term “stable” as used herein refers to physical stability and/orchemical stability of the active agent in a topical composition, whereinchanges in the drug assay values and/or impurities content are less thanabout 10%, during stability study storage of the composition at 25° C.and 60% relative humidity (RH), or 30° C. and 65% RH, or 40° C. and 75%RH, for durations such as 3, 6, 12, 18, or 24 months.

The term “propellant free” as used herein indicates that thecompositions are not delivered in admixture with any of the commonlyused aerosol propellants, such as fluorochlorohydrocarbons,hydrocarbons, compressed gases, and the like.

The term “substantially free” as used herein indicates that a specifiedsubstance referred to is present in amounts not more than 10% by weightof the total composition.

Aspects of the present application provide pharmaceutical topicalcompositions comprising at least one steroid as an active agent, whichis non-irritating to the skin, non-toxic, and well-tolerated.

In an aspect, the present application provides pharmaceutical topicalspray compositions comprising at least one steroid as an active agent,the compositions being propellant-free and/or substantially non-foaming.

In an aspect, the compositions of the present application are aqueousbased emulsion sprays.

In an aspect, a steroid is present in its acid or base form, its saltform, its ester form, its isomer form, or as a prodrug thereof.

In embodiments, a steroid of the present application is betamethasone,or a salt, ester, isomer, derivative, or prodrug thereof.

In embodiments, betamethasone is present in the form of betamethasonedipropionate.

In embodiments, a steroid of the present application is mometasonefuroate.

In embodiments, a steroid of the present application is betamethasonevalerate.

In embodiments, a steroid of the present application is triamcinoloneacetonide.

In embodiments, a steroid of the present application is alclometasonedipropionate.

In an aspect, an active agent can be added in an amorphous form,crystalline form, or mixtures thereof.

In an aspect, a composition of the present application is easilymanufactured, non-irritating to the skin, non-toxic, and well-tolerated,thereby providing a high degree of patient compliance, and is useful inthe prophylaxis, amelioration or treatment of skin diseases or disorderssuch as psoriasis, steroid responsive dermatoses, erythema, contactsensitivity reactions, and other associated diseases or disorders.

In an aspect, formulations of the present application provide sustainedrelease of the active agent, for better skin permeation and patientcomfort.

In embodiments, compositions of the present application aresubstantially alcohol-free and/or propylene glycol-free.

In an aspect, compositions of the present application are physically andchemically stable for commercially relevant times.

In an aspect, the present application provides methods of usingpropellant-free topical spray compositions comprising at least onesteroid as an active agent, methods comprising administering apharmaceutically effective amount of a spray composition directly ontoan affected part of the skin of a subject in need thereof.

In an aspect, pharmaceutical topical spray compositions of the presentapplication are useful in the management of psoriasis, and further canprovide a moisturizing and/or soothing effect at the site of applicationto the skin. In an aspect, a composition reduces the dryness thataccompanies the build-up of skin in psoriatic plaques. In an aspect, acomposition can be applied directly to the psoriatic lesions ordermatoses and can help reduce inflammation, remove built-up scale,reduce skin turnover, and/or clear affected skin of plaques.

In an aspect, the present application provides propellant-free topicalcompositions in a sprayable form, comprising at least one active agent,at least one solvent, at least one emulsifying agent, at least onepolymer, and at least one skin penetration enhancer in an amount ofabout 0.001 to about 15%, by weight, wherein a composition provides anenhanced flux of the active agent through the localized region of thebody surface to reach the dermis layer, thus being useful in theprophylaxis, amelioration, or treatment of skin diseases or disorders.

In embodiments, a penetration enhancer is present in a composition inamounts about 0.05 to about 10%, by weight. In embodiments, apenetration enhancer is present in a composition in amounts about 3% toabout 10%, by weight.

In an aspect, the skin diseases or disorders treated using compositionsof the application include psoriatic plaques, steroid responsivedermatoses, erythema, contact sensitivity reactions, and otherassociated diseases or disorders.

In an aspect, the skin diseases or disorders treated using compositionsof the application include atopic dermatitis, seborrhoeic dermatitis,eczema, plaque psoriasis, erythrodermic psoriasis, psoriasis of thescalp, and any combinations thereof.

In an aspect, the present application provides methods of prophylaxis,amelioration, or treatment of skin diseases or disorders, comprisingadministering a pharmaceutically effective amount of a spray compositionto a subject in need thereof. In aspects, the skin diseases or disordersare psoriasis, steroid responsive dermatoses, erythema, contactsensitivity reactions, and other associated diseases or disorders.

In embodiments, compositions of the present application comprise one ormore additional active agents that are useful in the management ofpsoriasis and associated pathological conditions including synthetic,semi-synthetic, or naturally obtained active agents.

The compositions of the present application can be used for prophylaxis,amelioration, or treatment of skin diseases and disorders, comprisingadministering a pharmaceutically effective amount of a spray compositionto a subject in need thereof. The compositions of the presentapplication are also useful in conjunction with other therapies, such asphototherapy.

In embodiments, compositions of the present application are easilywater-washable and removable from the site of application. Inembodiments, compositions of the present application, when applied byspraying onto the skin, are substantially non-occlusive to the skin.

In embodiments, compositions of the present application aresubstantially alcohol-free and/or propylene glycol-free, such that anyamounts present do not cause significant skin irritation or impart anyundesired attributes to the composition.

In embodiments, compositions comprise at least one steroid as an activeagent and one or more excipients, in the form of topical sprays.Concentrations of an active agent contained in a composition of thepresent application range from about 0.01% to about 10%, or from about0.025% to about 0.5%, by weight.

An aspect of the present application provides dispensing devicescontaining propellant-free topical compositions, wherein a devicecomprises a container, a pump dispenser, a dip tube, a metering valve,and an actuator, and wherein the pump dispenser is capable of dispensingthe composition through a dip tube into a metering valve, and throughthe actuator fitted with an orifice, such that the composition isconsistently released in the form of a substantially uniform spray.

An aspect of the present application provides dispensing devicescontaining a propellant-free topical composition; wherein the devicescomprise a container having therein a pouch system or bag filled withthe composition, optionally fitted with a dip tube and an actuatorfitted with a valve, the container being filled with a gas such asnitrogen gas or compressed air, surrounding the pouch or bag.Introduction of the composition into the system can further increase thepressure of the system, which is capable of dispensing the compositionfrom the pouch or bag into the actuator fitted with a valve, such thatthe composition is released upon actuation in the form of a spray.

An aspect of the present application provides processes for preparingpropellant-free topical compositions in sprayable form, comprising atleast one steroid as an active agent.

In embodiments, advantages of topical sprayable formulations of thepresent application include one or more of non-irritancy to the site ofapplication, ease of application, usefulness for long periods,non-staining of fabrics, and not possessing a strong or objectionableodour. This facilitates a subject in need thereof to maintain regularapplications of the medications, thus avoiding abrupt withdrawal of thesteroidal composition applications, which in turn prevents an aggressiverecurrence of the disease condition.

In embodiments, compositions of the application comprise at least onesteroid drug, such as alclometasone dipropionate, amcinonide,beclomethasone dipropionate, betamethasone benzoate, betamethasonedipropionate, betamethasone sodium phosphate, betamethasone valerate,budesonide, clobetasol propionate, clobetasone butyrate, clocortolonepivalate, desonide, desoximetasone, dexamethasone, dexamethasoneacetate, dexamethasone nicotinate, dexamethasone propionate,dexamethasone sodium phosphate, dexamethasone valerate, diflorasonediacetate, diflucortolone valerate, fluandrenolide, flumethasonepivalate, fluocinolone acetonide, fluocinonide, fluocortin butyl ester,fluticasone propionate, halcinonide, halobetasol propionate,halometasone monohydrate, hydrocortisone, hydrocortisone sodiumphosphate, hydrocortisone sodium succinate,hydrocortisone-17-butyrate-21-propionate, hydrocortisone aceponate,hydrocortisone acetate, hydrcortisone valerate, hydrocortisone butyrate,hydrocortisone probutate, methylprednisolone, methylprednisoloneacetate, methylprednisolone aceponate, mometasone furoate, prednisolone,prednisolone sodium phosphate, prednisolone acetate,prednisolone-17-valerate-21-acetate, triamcinolone acetonide,triamcinolone acetate, triamcinolone diacetate, and prednicarbate. Otherdrug compounds are also useful, and this application furtherspecifically contemplates the use of any combinations of steroid drugs.

According to the invention, unless otherwise specified, recitation of anactive agent, such as a steroid, is intended to include the drugcompound or any salts, esters, isomers, conjugates, derivatives orprodrugs thereof.

The active agent generally is present in amounts about 0.01% to about1%, by weight of the composition. However, other amounts are useful,depending on the potency of the active agent and the conditions to betreated.

In embodiments, a steroid present in the topical compositions isbetamethasone dipropionate, which typically is administered in doses ofabout 0.001 mg/Kg body weight to about 0.5 mg/Kg body weight, to asubject in need thereof.

In embodiments, a steroid is betamethasone dipropionate, present intopical compositions in concentrations about 0.064% by weight, althoughhigher or lower amounts may be used as desired, for example from about0.01% to about 0.5% by weight, or from about 0.02% to about 0.07% byweight. In embodiments, a betamethasone compound used in the presentapplication is present in compositions in amounts equivalent to about0.025% to about 0.1%, or about 0.05%, by weight of betamethasone base.

In embodiments, compositions of the present application are formulatedas emulsions, comprising an oily or hydrophobic phase, an aqueous orhydrophilic phase, and an emulsifier. When the oily phase is dispersedas droplets within an aqueous continuous phase, this is called an“oil-in-water” type of emulsion. When the aqueous phase is dispersed asdroplets within an oily continuous phase, this is called an“water-in-oil” type of emulsion. In embodiments, the hydrophobic phasecomprises about 0.5% to about 90% by weight of the composition.Compositions in the form of emulsions may be micro- or nano-emulsions.In embodiments, average particle sizes of the dispersed phase dropletsare less than about 500 μm. In embodiments, average particle sizes ofthe dispersed phase droplets are less than about 2000 nm.

In embodiments, compositions of the present application includeexcipients including, but not limited to, one or more of carriers,emulsifiers, coemulsifiers, permeation or penetration enhancers,solvents, co-solvents, emollients, antioxidants, preservatives,buffering agents, gelling or thickening agents, polymers, surfactants,soothing agents, pH modifiers, solubilizers, humectants, emollients,moisturizers, oily bases, and the like.

“Emollients” are substances that soften and soothe the skin. They areused to correct dryness and scaling of the skin. Various emollientsinclude, but are not limited to, oils of natural origin such as almondoil, coconut oil, olive oil, palm oil, peanut oil and the like, fattyacids such as lauric acid, myristic acid, palmitic acid, and stearicacid, monohydric alcohol esters of the fatty acids such as ethyllaurate, isopropyl laurate, ethyl myristate, n-propyl myristate,isopropyl myristate, ethyl palmitate, isopropyl palmitate, methylpalmitate, methyl stearate, ethyl stearate, isopropyl stearate, butylstearate, isobutyl stearate, amyl stearate, and isoamyl stearate,glycols such as ethylene glycol, diethylene glycol, polyethylene glycol,and propylene glycol, branched aliphatic alcohols such as laurylalcohol, myristyl alcohol, and stearyl alcohol, and any combinationsthereof.

The term “carrier” denotes organic or inorganic ingredients, natural orsynthetic, with which an active ingredient is combined to facilitateapplication of a composition. The term “carrier” includes, but is notlimited to, one or more of water, acetone, alone or in combination withmaterials such as silicone fluids. The amounts of carrier may be about5% to about 99% of the total weight of the composition. In embodiments,a carrier according to the present application comprises water. Inembodiments, the carrier can comprise, in addition to water,water-immiscible substances such as any pharmaceutically acceptablefatty esters of natural fatty acids, triglycerides of animal orvegetable, medium chain triglycerides, mixtures of mono-, di- and/ortriglycerides, waxes, hydrogenated vegetable oils, and mixtures thereof.

Examples of suitable polymers for use in the compositions include, butare not limited to carbomers, polyethylene glycols, acrylate polymers,methacrylate polymers, polyvinylpyrrolidones, copolymers based on butylmethacrylate and methyl methacrylate povidone, vinyl acetates, polyvinylacetates, celluloses, gums, alginates, cellulose acetate phthalates,cellulose acetate butyrates, hydroxypropyl methyl cellulose phthalates,and the like. Examples include Carbopol® products, PEG 400, Eudragit®100, Eudragit® RSPO, Eudragit® RLPO, Eudragit® ND40, Plasdone®,copolymers based on butyl methacrylate and methyl methacrylate(Plastoid® B), alkyl celluloses such as ethyl celluloses and methylcelluloses, hydroxyalkyl celluloses such as hydroxyethyl cellulose andhydroxypropyl cellulose, hydroxyalkyl alkyl celluloses such ashydroxypropyl methylcelluloses and hydroxybutyl methylcelluloses, gumssuch as xanthan gum, tragacanth, guar gum, locust bean gum, acacia, andthe like. The amount of polymer may be about 0.5 to about 50% by weightof the total weight of the composition.

Other polymers that are useful include polyamides, polycarbonates,polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkyleneterepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters,polyvinyl halides, polyglycolides, polysiloxanes, polyurethanes andcopolymers thereof, cellulose ethers, cellulose esters, nitrocelluloses,polymers of acrylic and methacrylic esters, cellulose acetates,cellulose propionates, cellulose acetate butyrates, cellulose acetatephthalates, carboxylethyl celluloses, cellulose triacetates, cellulosesulphate sodium salts, poly(methyl ethacrylate),poly(ethylmethacrylate), poly(butylmethacrylate),poly(isobutylmethacrylate), poly(hexylmethacrylate),poly(isodecylmethacrylate), poly(lauryl methacrylate), poly(phenylmethacrylate), poly(methyl acrylate), poly(isopropyl acrylate),poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylenes,polypropylenes, poly(ethylene glycol), poly(ethylene oxide),poly(ethylene terephthalate), poly(vinyl alcohol), poly(vinyl acetate),poly(vinyl chloride), polystyrenes, and the like, including any mixturesthereof.

Examples of other useful polymers include synthetic polymers, such aspolymers of lactic acid and glycolic acid, polyanhydrides, poly(orthoester), polyurethanes, poly(butyric acid), poly(valeric acid),poly(caprolactone), poly(hydroxybutyrate), poly(lactide-co-glycolide),poly(lactide-co-caprolactone), and natural polymers such as alginate andother polysaccharides that include but are not limited to arabinans,fructans, fucans, galactans, galacturonans, glucans, mannans, xylans(such as, for example, inulin), levan, fucoidan, carrageenan,galatocarolose, pectic acid, pectin, amylose, pullulan, glycogen,amylopectin, cellulose, dextran, pustulan, chitin, agarose, keratan,chondroitan, dermatan, hyaluronic acid, alginic acid, xanthan gum,starches, and various other natural homopolymers and heteropolymers,such as those containing one or more of aldoses, ketoses, acids oramines, erythrose, threose, ribose, arabinose, xylose, lyxose, allose,altrose, glucose, mannose, gulose, idose, galactose, talose,erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose,mannitol, sorbitol, lactose, sucrose, trehalose, maltose, cellobiose,glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine,aspartic acid, glutamic acid, lysine, arginine, histidine, glucuronicacid, gluconic acid, glucaric acid, galacturonic acid, mannuronic acid,glucosamine, galactosamine, and neuraminic acid, and naturally occurringderivatives thereof, and including dextran and cellulose, collagen,albumin and other hydrophilic proteins, zein and other prolamines andhydrophobic proteins, copolymers and mixtures thereof.

The content of polymer may be about 0.01% to about 45% of the totalweight of the composition.

Examples of suitable emulsifying agents include, but are not limited to,disodium cocoampho diacetate, oxyethylenated glyceryl cocoate (7 EO),PEG-20 hexadecenyl succinate, PEG-15 stearyl ether, ricinoleicmonoethanolamide monosulfosuccinate salts, oxyethylenated hydrogenatedricinoleic triglyceride containing 60 ethylene oxide units such as theproducts sold by BASF under the trademarks Cremophor® RH 60 orCremophor® RH 40 (polyoxyl 40 hydrogenated castor oil), polymers such aspoloxamers, which are block copolymers of ethylene oxide and propyleneoxide, and the nonsolid fatty substances at room temperature (that is tosay, at temperatures ranging from about 20 to 35° C.) such as sesameoil, sweet almond oil, apricot stone oil, sunflower oil, octoxyglycerylpalmitate (or 2-ethylhexyl glyceryl ether palmitate), octoxyglycerylbehenate (or 2-ethylhexyl glyceryl ether behenate), dioctyl adipate, andtartrates of branched dialcohols. Sorbitan fatty acid esters are aseries of mixtures of partial esters of sorbitol and its mono- anddianhydrides with fatty acids. Sorbitan esters include products sold asArlacel® 20, Arlacel 40, Arlacel 60, Arlacel 80, Arlacel 83, Arlacel 85,Arlacel 987, Arlacel C, PEG-6 stearate and glycol stearate and PEG-32stearate (Tefose® 63), and PEG-6 stearate and PEG-32 stearate (Tefose®1500), and any mixtures thereof. Polyethylene glycol ethers of stearicacid are in another group of emulsifiers that can be used in theemulsions. Examples of polyethylene glycol ethers of stearic acid aresteareth-2, steareth-4, steareth-6, steareth-7, steareth-10,steareth-11, steareth-13, steareth-15, steareth-20, polyethylene glycolethers of stearyl alcohol (steareth 21), and any mixtures thereof. Otheremulsifying agents include sodium lauryl sulphate, cetyl trialkylammonium bromide, polyoxyethylene sorbitan fatty acid esters, and anymixtures thereof. Amounts of emulsifier may be about 0.25% to about 45%of the total weight of the compositions.

Nonionic emulsifying agents include those that can be broadly defined ascondensation products of long chain alcohols, e.g., C₈₋₃₀ alcohols, withsugar or starch polymers, i.e., glycosides. Various sugars include, butare not limited to, glucose, fructose, mannose, and galactose, andvarious long chain alcohols include, but are not limited to, decylalcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristylalcohol, oleyl alcohol, and the like.

Other useful nonionic emulsifying agents include condensation productsof alkylene oxides with fatty acids such as alkylene oxide esters offatty acids. Other nonionic surfactants are the condensation products ofalkylene oxides with 2 moles of fatty acids such as alkylene oxidediesters of fatty acids.

Emulsifying agents can also include any of a wide variety of cationic,anionic, zwitterionic, and amphoteric surfactants that are known in theart. Non-limiting examples of anionic emulsifying agents include alkylisethionates, alkyl and alkyl ether sulfates and salts thereof, alkyland alkyl ether phosphates and salts thereof, alkyl methyl taurates, andsoaps (e.g., alkali metal salts and sodium or potassium salts) of fattyacids.

Examples of amphoteric and zwitterionic emulsifying agents include thosewhich are broadly described as derivatives of aliphatic secondary andtertiary amines in which the aliphatic radical can be straight orbranched chain, wherein one of the aliphatic substituents contains fromabout 8 to about 22 carbon atoms and one contains an anionic watersolubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, orphosphonate. Specific examples include alkylimino acetates,iminodialkanoates and aminoalkanoates, imidazolinium and ammoniumderivatives. Other suitable amphoteric and zwitterionic emulsifyingagents include betaines, sultaines, hydroxysultaines, alkylsarcosinates, and alkanoyl sarcosinates.

Silicone emulsifying agents are typically organically modifiedorganopoly siloxanes, sometimes called silicone surfactants. Usefulsilicone emulsifying agents include dimethicone copolyols. Thesematerials are polydimethyl siloxanes, which have been modified toinclude polyether side chains such as polyethylene oxide chains,polypropylene oxide chains, mixtures of these chains, and polyetherchains containing moieties derived from both ethylene oxide andpropylene oxide.

The amounts of emulsifier may be about 0.25% to about 45% of the totalweight of the composition.

Co-emulsifiers or secondary emulsifying agents includepolyoxylglycerides such as oleoyl macrogolglycerides (Labrafil® M1944CS), linoleoyl macrogolglycerides (Labrafil® M 2125CS),caprylocaproyl macrogolglycerides (Labrasol®), cetyl alcohol (and)ceteth-20 (and) steareth-20 (Emulcire™ 61 WL 2659), glyceryl stearate(and) PEG-75 stearate (Gelot® 64), and any mixtures thereof.

A “permeation enhancer” or “penetration enhancer” is a component used toenhance the penetration rate of drugs through the skin or mucousmembrane, such as by temporarily diminishing the impermeability of theskin or membrane. Permeation enhancers have also been called“accelerants” and “absorption promoters.” There are numerous penetrationenhancers that can be used. Various useful permeation enhancers include,for example: polyols and esters, including polyethylene glycol,polyethylene glycol monolaurate, and butanediol; sulfoxides, includingdimethylsulfoxide and decylmethylsulfoxide; ethers, including diethyleneglycol monoethyl ether (e.g., Transcutol® P) and diethylene glycolmonomethyl ether; fatty acids, including lauric acid, oleic acid, andvaleric acid; fatty acid esters, including isopropyl myristate,isopropyl palmitate, methyl propionate, and ethyl oleate; nitrogenouscompounds including urea, dimethyl acetamide, dimethylformamide2-pyrrolidone, ethanolamine, methyl-2-pyrrolidone, diethanolamine, andtriethanolamine; terpenes; alkanones; organic acids, including salicylicacid, citric acid, and succinic acid; and any mixtures thereof. Further,one or more surfactants can also be used as a permeation or penetrationenhancer. A permeation enhancer can be used in concentrations rangingfrom about 0.001-15%, or about 0.05-12%, or about 3-10%, of the totalweight of the composition.

The term “preservative” refers to a natural or synthetic chemical thatis added to products to prevent decomposition by microbial growth or byundesirable chemical changes. Preservatives can desirably beincorporated into a composition for protecting against the growth ofpotentially harmful microorganisms. While microorganisms tend to grow inan aqueous phase, microorganisms can also reside in a hydrophobic or oilphase. Suitable preservatives for compositions of the present inventioninclude, but are not limited to, methylparaben, propylparaben, benzylalcohol, chlorocresol, benzalkonium chloride, cetrimonium chloride,sodium edetate, boric acid, and any mixtures thereof. The amount ofpreservative may be about 0.25% to about 25% of the total weight of thecomposition.

Antioxidants are substances which inhibit oxidation or suppressreactions promoted by oxygen or peroxides. Antioxidants, especiallylipid-soluble antioxidants, can be absorbed into the cellular membraneto neutralize oxygen radicals and thereby protect the membrane. Suitableantioxdants for compositions of the present invention include, but arenot limited to, ascorbic acid (vitamin C), glutathione, lipoic acid,uric acid, carotenes, α-tocopherol (vitamin E), ubiquinol, butylatedhydroxyanisole, butylated hydroxytoluene, sodium benzoate, propylgallate (PG, E310), and tertiary-butylhydroquinone. The amounts ofantioxidant may be about 0.01% to about 20%, of the total weight of thecomposition.

“Solvent” refers to components that aid in the dissolution of the drugin the formulation. Solvents serve to maintain a solution of the drug inthe composition. Some solvents can also enhance percutaneous penetrationof drug and/or act as humectants. For steroid drugs, solvents caninclude water-immiscible substances such as fatty esters of naturalfatty acids, triglycerides of animal or vegetable, medium chaintriglycerides, mixtures of mono-, di- and/or triglycerides, waxes,hydrogenated vegetable oils, and mixtures thereof. Some specificexamples include castor oil, lanolin oil, citrate triisocetyltriglycerides having 10-18 carbon atoms, caprylic/capric triglycerides,coconut oil, corn oil, cottonseed oil, linseed oil, oil of mink, oliveoil, palm oil, sunflower oil, nut oil, diethylene glycol monoethylether, diethylene glycol monomethyl ether, saturated paraffin oils,light or heavy mineral oils, vegetable oils or glycerides, and the like.

Some of the excipient substances described above can have more than onefunction in a formulation. For example, a substance can be both asolvent and a penetration enhancer, or both a solvent and a carrier. Thecategorizations of materials described above are not to be construed aslimiting or restricting in any manner.

The compositions of the present application may be in the form ofsolutions, suspensions, emulsions, lotions, microemulsions,nanoemulsions, emulgels, gels, and the like. In embodiments,compositions may be in the form of an emulsion. The emulsion can be inthe form of an oil-in-water type of emulsion or a water-in-oil type ofemulsion. An aqueous-based emulsion, such as an oil-in-water emulsion,frequently has lower viscosity than other emulsion types and exhibitsappreciable storage stability. Generally, oil-in-water emulsions havebetter skin feel properties, when applied to the skin, as these givesensations similar to an aqueous material.

The compositions can be applied directly onto affected areas of theskin, such as psoriatic plaques or dermatoses. Sprayable compositions,upon being sprayed, form droplets on the affected areas and, inembodiments, can provide release of the active agent for an extendedduration of time. Viscosities of aqueous-based emulsions of the presentapplication frequently vary in the range of about 0.01-15 Pascal second,“Pa·s” (10-15,000 centipoise, “cP”), about 0.1-1.5 Pa·s (100-1,500 cP),or about 0.2-1 Pa·s (200-1,000 cP).

Aspects of the present application also provide dispensing devices forthe topical delivery of the compositions onto the skin in the form ofsprays. In embodiments, the present application provides devices, intowhich the compositions are filled, comprising a container, a dispenser,and a closure.

In embodiments, the closures used for packaging are made of a polymericsubstance such as high-density polyethylene (HDPE), low-densitypolyethylene (LDPE), or resins. The closures are particularly in theform of caps that are fitted onto the containers to aid in providingsupport to the dispenser unit and/or to shield the contents of thecontainer from the outside environment. Various container materialsinclude, but are not limited to, tin plated steel, aluminum, stainlesssteel, plastics, and glass.

An example of a dispenser is a unit containing a pump that can beadapted to fit on any type of container, such as by threads that matchthreading on the container. The pump is capable of dispensing sprayablecompositions of the present application through a dip tube extendinginto a container from an actuator and attached to a one-way valve, whichreleases the composition from an orifice in the actuator in the form ofa spray. The valve may be a metering valve.

Various types of valves that can be used include, but are not limitedto, continuous spray valves and metering valves. The actuators allow foreasy opening and closing of the valve and are an integral part of apackage. This also serves to aid in producing the required type ofproduct discharge. Various types of actuators include but are notlimited to spray actuators, foam actuators, solid-stream actuators, andspecial actuators.

In an embodiment a dispensing device may be a device comprising acontainer, having therein a pouch system or bag containing the product,optionally fitted with a dip tube and an actuator fitted with a valvewherein the container is filled with nitrogen gas or compressed air,surrounding the pouch or bag. Containers can be made of aluminum or tinplate and the pouch system or bag containing the product can be made oflayers of polyethylene (PE), polypropylene (PP), polyethyleneterephthalate (PET), and aluminum. Introduction of the composition intothe system further increases the pressure of the system which is capableof dispensing the composition from the pouch into the actuator, fittedwith a valve, such that the composition is consistently released in theform of a substantially uniform spray upon actuation. The pouch can havea dip tube therein, communicating with the actuator valve, to controlthe spray rate and reduce droplet size.

In embodiments, a dispensing device useful for dispensing thecompositions of the present application provides spray rates and spraypatterns, in a manner such that substantially uniform dosage isdispensed each time which appreciably covers the desired affected areaof the skin onto which the composition is sprayed. The pump is intendedto deliver the composition uniformly onto the skin. It covers a desiredarea of the skin and produces very fine uniform droplets, at a specifiedspray rate such as, but not limited to, about 20 to about 500mg/actuation, or about 100 to about 200 mg/actuation. The deviceprovides a reproducible spray pattern, such as circular, frequentlycovering an area of about 0.1 to about 10 cm² depending on the distancefrom the application site.

About 2-6 priming actuations can be required for a new pump toreproducibly dispense the compositions. In a specific embodiment, about160 μL it of a formulation is dispensed, per actuation of the pump.Devices frequently provide a reproducible distribution of droplets, indistributions where about 90% of the droplets have sizes ranging fromabout 1 to about 500 μm.

The orifice is sized to control the droplet sizes of the dispensedproduct. The orifice size also affects providing of a uniformcharacteristic spray pattern.

In embodiments, the compositions useful in treating psoriasis may bepackaged in a bottle fitted with an attached spray pump closure that canbe mechanically actuated by a patient or caregiver, to apply thecomposition to the affected skin (i.e., a pump-type spray closure).

In embodiments, a spray formulation of the present application can beapplied in an essentially easier and more exact way than creams andointments can be applied, since for the spray application it is onlynecessary to spray a given volume, whereas the application of thesemi-solid products requires an easily accessible and visual estimationof the cream amount or the ointment amount. Further, smearing andsoiling of clothing can more easily be avoided on large surface areas.For the spray compositions, spreading and rubbing are not necessarilyrequired, contrary to cream and ointment products, since the layerformed on the body surface by evaporation or vaporization of the liquidalready has an ideal fine dispersion of active agent; hence ‘pressurepain’ will not occur from the topical application of spray compositionsof the present application.

In an aspect, aqueous based emulsion sprayable formulations of thepresent application also permit applying a medicament by a methodwhereby the area of application is contacted by only the spray.

In an aspect, topical application of compositions of the presentapplication forms a depot on the skin without forming an occlusive film,thereby extending the duration of active agent action while allowing‘breathing’ of the skin.

Aspects of the present application further provide processes forpreparing compositions that can be filled into suitable dispensingdevices. In embodiments, processes comprise:

a) preparing a composition comprising the active agent and one or moresuitable excipients, and

b) filling a desired quantity of the composition into a dispensingdevice.

In embodiments, processes for preparing topical compositions comprisingbetamethasone as an active agent and excipients comprise:

a) heating a mixture comprising an emulsifying agent and a solvent toobtain an oily phase;

b) optionally, admixing an antioxidant and/or preservative into the oilyphase of a);

c) admixing an active agent with a penetration enhancer;

d) admixing the material of c) with material of a) or b);

e) dissolving a polymer in an aqueous phase;

f) admixing the oily phase of d) slowly with the aqueous phase of e)with continuous mixing; and

g) homogenizing the mixture of f), followed by cooling.

In embodiments, compositions of the present application have pH valuesranging from about 3 to about 7, or about 3.5 to about 6.

In embodiments, the oily phase for an emulsion is a mixture ofemulsifying agents and a solvent.

In embodiments, betamethasone spray compositions of the presentapplication exhibit a comparable drug dissolution profile to that of acommercial DIPROLENE® lotion, a product of Schering Corporation,containing 0.05% betamethasone (in the form of betamethasonedipropionate), water, isopropyl alcohol (30%), hydroxypropyl cellulose,propylene glycol, sodium phosphate, phosphoric acid, and sodiumhydroxide.

In embodiments, betamethasone propionate formulations of the presentapplication may contain any one or more of impurities, such as impurityA (betamethasone 17-propionate) in amounts not more than about 5%,impurity B (betamethasone 21-propionate) in amounts not more than about2%, impurity C (betamethasone 17-propionate 21-acetate) in amounts notmore than about 1%, and impurity D (betamethasone 21-valerate) inamounts not more than about 1%, these impurities having the structuresshown in FIG. 3, and any other drug-related impurities, in amounts suchthat any such impurities do not substantially adversely affect thesafety of the composition. Impurities A and B are primarily observedduring stability studies of a formulation, and impurities C and D aregenerally process-related impurities from synthesis of the drug. Theabove impurity limits are expressed as percentages of the label drugcontent in the formulation.

The following examples are provided to illustrate certain specificaspects and embodiments of the application, and are not to be construedas limiting the scope of the application in any manner. In the examples,the active agent betamethasone dipropionate used has a particle sizedistribution wherein half of the particles have sizes less than about 50μm, and 90% of the particles have sizes less than about 300 μm.

Example 1 Betamethasone Spray Formulations

Wt. Percent Ingredient A B Betamethasone dipropionate 0.064 0.064Polyethylene glycol and ethylene 7.5 7.5 glycol palmitostearate Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.3 76.3

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Betamethasone dipropionate is mixed with diethylene glycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Comparative in vitro dissolution profile testing, showing drug releasefrom Formulation A and Formulation B, and a commercial referenceproduct, is conducted. The reference product is DIPROLENE® lotion. Thetest procedure is as described below.

A Franz diffusion cell is fitted with a polysulphone 0.2 μm membraneclamped between the donor and receptor compartments. The receptor mediais a mixture of ethanol and water (20:80 by volume) with a replacementvolume of 12.0 mL, sampling volume of 2.0 mL at the times 30, 60, 120,240, and 360 minutes, and the temperature maintained at 32±0.5° C. About200 mg of the formulation is applied uniformly over the membrane using asyringe. The donor compartment is covered using Parafilm® (hydrocarbonwax and polyolefin blend). Receptor fluid is analyzed for the drug,using high performance liquid chromatography (HPLC).

TABLE 1 Cumulative % of Drug Released Minutes DIPROLENE Formulation AFormulation B 30 28.6 1.6 1.0 60 66.5 3.3 3.7 120 100.3 5.65 8.2 240117.9 10.8 15.6 360 123.8 15.5 22.4

Drug release from DIPROLENE lotion is rapid. However, from Formulation Aand Formulation B, betamethasone release is slow and sustained overseveral hours. The results are plotted in FIG. 1. A release lag timeremains below 30 minutes in all of the compositions tested, and isassumed to be contributed mainly from the polymeric membrane used forrelease testing. The rates of drug release, fitted to the Higuchiequation, for Formulations A and B, are shown in Table 2.

TABLE 2 Release Rate Release Lag (μg/cm² · Time Regression Formulationmin^(0.5)) (minutes) Coefficient A 1.023 20.4 0.984 B 1.587 28.2 0.993

The prepared formulations, filled into closed containers, are exposed tothe stability testing conditions 25° C. and 60% relative humidity (RH),30° C. and 65% RH, and 40° C. and 75% RH for three months, and analysesat various storage points are shown in Tables 3 and 4, where the valuesare percentages of the label drug content.

TABLE 3 Formulation A Storage Impurities Conditions Drug Assay A B C DTotal Initial — 99.08 — — — — 2.09 1 Month 25° C. 100.7 0.63 0.27 ND ND1.34 30° C. 100 0.73 0.28 ND ND 1.48 40° C. 99.36 0.92 0.25 ND ND 1.59 2Months 25° C. 103.5 0.78 0.39 ND ND 1.61 30° C. 102.4 0.89 0.3 ND ND1.77 40° C. 100.7 1.34 0.4 ND ND 2.62 3 Months 25° C. 101.3 0.57 0.24 NDND 1.54 30° C. 101.6 0.76 0.26 ND ND 1.72 40° C. 100.6 1.52 0.34 ND ND2.18 ND = not detected.

TABLE 4 Formulation B Impurities Storage Drug Assay A B C D TotalInitial — 101.81 — — — — 1.52 1 Month 25° C. 99.5 0.32 0.26 ND ND 0.7530° C. 103.2 0.33 0.29 ND ND 0.61 40° C. 103.4 0.41 0.35 ND ND 0.76 2Months 25° C. 102.3 0.34 0.32 ND ND 1.04 30° C. 102.3 0.34 0.31 ND ND0.65 40° C. 102.5 0.59 0.36 ND ND 0.95 3 Months 25° C. 99.4 0.31 0.29 NDND 0.99 30° C. 99.6 0.37 0.32 ND ND 1.1 40° C. 98.2 0.74 0.33 ND ND 1.83ND = not detected.

Example 2 Betamethasone Spray Formulations

Wt. Percent Ingredient C D E F G Betamethasone 0.032 0.064 0.064 0.0640.064 dipropionate PEG-6 palmitostearate 7.5 7.5 7.5 7.5 7.5 (and)ethylene glycol palmitostearate (and) PEG-32 palmitostearate Mineral oil7.06 7.06 7.06 7.06 7.06 Oleoyl 2.94 2.94 2.94 2.94 2.94polyoxylglycerides Diethyleneglycol 3 5 7 3 10 monoethyl etherPropylparaben 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.2 0.2 0.2 0.2 0.2Butylated 0.05 0.05 0.05 0.05 0.05 hydroxytoluene Hydroxyethyl cellulose0.1 0.1 0.1 0.1 0.1 Water 78.31 76.28 74.28 78.28 71.28

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Betamethasone dipropionate is mixed with diethyleneglycol monoethylether.

d) Material of c) is mixed with material of b).

e) Hydroxyethyl cellulose is dissolved in water.

f) The oily phase of d) is slowly added to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

A stability study is conducted for Formulation D, involving storing theformulation for 3 months in closed containers at the conditions 25° C.and 60% RH, 30° C. and 65% RH, and 40° C. and 75% RH. All samples remainoff-white homogenous emulsions with no phase separation. Drug assayvalues are within the specified limits of 90-110% of the label drugcontent for all samples, as shown in Table 5, where all values arepercentages of the label drug content. The pH of the samples remainsbetween 3 and 6. Viscosity values, measured at 100 rpm using aBrookfield CAP 2000+ viscometer, remain close to the original values forall samples.

TABLE 5 Impurities Storage Drug Assay A B C D Total Initial — 101.6 — —— — 0.14 1 Month 25° C. 102.6 0.56 0.03 0.09 ND 0.68 30° C. 100.7 0.630.03 0.09 ND 0.74 40° C. 97.7 1.32 0.04 0.09 ND 1.45 2 Months 25° C.100.9 0.77 ND 0.08 ND 0.85 30° C. 100.7 0.91 0.02 0.08 ND 1.02 40° C.98.7 2.04 0.11 0.07 ND 2.22 3 Months 25° C. 101.3 1.04 0.05 0.02 ND 1.1730° C. 100.5 1.22 0.05 0.02 ND 1.29 40° C. — 2.92 0.26 0.01 ND 3.24 ND =not detected.

Example 3 Betamethasone Spray Formulations

Wt. Percent Ingredient H I J K Betamethasone dipropionate 0.032 0.0640.064 0.064 PEG-6 palmitostearate (and) 7.5 7.5 7.5 7.5 ethylene glycolpalmitostearate (and) PEG-32 palmitostearate Mineral oil 7.06 7.06 7.067.06 Oleoyl polyoxylglycerides 2.94 2.94 2.94 2.94 Diethyleneglycolmonoethyl ether 3 5 7 3 Propylparaben 0.8 0.8 0.8 0.8 Methylparaben 0.20.2 0.2 0.2 Butylated hydroxytoluene 0.05 0.05 0.05 0.05 Xanthan gum 0.10.1 0.1 0.1 Water 78.31 76.28 74.28 78.28

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Betamethasone dipropionate is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Xanthan gum is dissolved in water.

f) The oily phase of d) is slowly added to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of (f) is homogenized and allowed to cool to ambienttemperature.

Example 4 Betamethasone Spray Formulations

Wt. Percent Ingredient L M N O P Betamethasone 0.064 0.064 0.064 0.0640.064 dipropionate PEG-6 palmitostearate 1.5 — — — 1.5 (and) ethyleneglycol palmitostearate (and) PEG-32 palmitostearate PEG-6 stearate and —— 1.5 1.5 — PEG-32 stearate Sorbitan stearate 2.5 2.5 2.5 2.5 2.5 PEGether of stearyl — 2.22 — — — alcohol Mineral oil 7.06 7.06 7.06 7.067.06 Oleoyl 2.94 2.94 2.94 — — polyoxylglycerides Cetyl alcohol (and) —— — 1 1 ceteth 20 (and) steareth 20 Diethyleneglycol 10 5 5 5 5monoethyl ether Propylparaben 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.2 0.20.2 0.2 0.2 Butylated 0.05 0.05 0.05 0.05 0.05 hydroxytolueneHydroxyethyl cellulose 0.1 0.1 0.1 0.1 0.1 Water 76.35 74.85 79.13 79.8581.79

Manufacturing Process:

a) Polyethylene glycol (and) ethylene glycol palmitostearate (and)PEG-32 palmitostearate, PEG-6 stearate and PEG-32 stearate, sorbitanstearate, PEG ether of stearyl alcohol, mineral oil, oleoylpolyoxyglycerides, and cetyl alcohol (and) ceteth 20 (and) steareth 20,as required, are mixed and heated to about 50-70° C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Betamethasone dipropionate is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 5 Mometasone Spray Formulations

Wt. Percent Ingredient AB 1 AB 2 Mometasone furoate 0.1 0.1 Polyethyleneglycol and ethylene glycol palmitostearate 7.5 7.5 Mineral oil 7.06 7.06Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycol monoethyl ether 5 5Propylparaben 0.8 0.8 Methylparaben 0.2 0.2 Butylated hydroxytoluene0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthan gum — 0.1 Water 76.2576.25

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Mometasone furoate is mixed with diethyleneglycol monoethyl ether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 6 Halobetasol Spray Formulations

Wt. Percent Ingredient AB 3 AB 4 Halobetasol propionate 0.05 0.05Polyethylene glycol and ethylene glycol 7.5 7.5 palmitostearate Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.3 76.3

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated at about 50-70°C.;

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Halobetasol propionate is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 7 Triamcinolone Spray Formulations

Wt. Percent Ingredient AB 5 AB 6 Triamcinolone acetonide 0.1 0.1Polyethylene glycol and ethylene glycol palmitostearate 7.5 7.5 Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.25 76.25

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are Mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Triamcinolone acetonide is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 8 Hydrocortisone Spray Formulations

Wt. Percent Ingredient AB 7 AB 8 Hydrocortisone butyrate 0.1 0.1Polyethylene glycol and ethylene glycol palmitostearate 7.5 7.5 Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.25 76.25

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Hydrocortisone butyrate is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 9 Betamethasone Spray Formulations

Wt. Percent Ingredient AB 9 AB 10 Betamethasone valerate 0.05 0.05Polyethylene glycol and ethylene 7.5 7.5 glycol palmitostearate Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.3 76.3

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Betamethasone valerate is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 10 Fluocinolone Spray Formulations

Wt. Percent Ingredient AB 11 AB 12 Fluocinolone acetonide 0.05 0.05Polyethylene glycol and ethylene 7.5 7.5 glycol palmitostearate Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.3 76.3

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Fluocinolone acetonide is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 11 Desonide Spray Formulations

Wt. Percent Ingredient AB 13 AB 14 Desonide 0.05 0.05 Polyethyleneglycol and ethylene 7.5 7.5 glycol palmitostearate Mineral oil 7.06 7.06Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycol monoethyl ether 5 5Propylparaben 0.8 0.8 Methylparaben 0.2 0.2 Butylated hydroxytoluene0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthan gum — 0.1 Water 76.3 76.3

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Desonide is mixed with diethyleneglycol monoethyl ether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 12 Methylprednisolone Spray Formulations

Wt. Percent Ingredient AB 15 AB 16 Methylprednisolone 0.1 0.1Polyethylene glycol and ethylene 7.5 7.5 glycol palmitostearate Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Diethyleneglycolmonoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 76.25 76.25

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Methylprednisolone is mixed with diethyleneglycol monoethyl ether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 13 Alclometasone Spray Formulations

Wt. Percent Ingredient AB 17 AB 18 Alclometasone dipropionate 0.0050.005 Polyethylene glycol and ethylene 7.5 7.5 glycol palmitostearateMineral oil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94Diethyleneglycol monoethyl ether 5 5 Propylparaben 0.8 0.8 Methylparaben0.2 0.2 Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 —Xanthan gum — 0.1 Water 76.3 76.3

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Alclometasone dipropionate is mixed with diethyleneglycol monoethylether.

d) The material of c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 14 Betamethasone Spray Formulations

Wt. Percent Ingredient AB 19 AB 20 Betamethasone dipropionate 0.05 0.05Ethanol 74.89 7 Isopropyl myristate 12 10 Transcutol ® P 5 12 Mineraloil 7.06 69.95 Acrylic polymer 1 1

Manufacturing Process:

a) Acrylic polymer is dissolved in ethanol.

b) Betamethasone dipropionate is dissolved in a mixture of isopropylmyristate, mineral oil, and Transcutol P, with stirring.

c) The mixtures of a) and b) are combined with continuous stirring toobtain the product.

Example 15 Mometasone Spray Formulations

Wt. Percent Ingredient AB 21 AB 22 Mometasone furoate 0.1 0.1Polyethylene glycol and ethylene 7.5 7.5 glycol palmitostearate Mineraloil 7.06 7.06 Oleoyl polyoxylglycerides 2.94 2.94 Transcutol P 5 12Propylene glycol 7 3 Propylparaben 0.8 0.8 Methylparaben 0.2 0.2Butylated hydroxytoluene 0.05 0.05 Hydroxyethyl cellulose 0.1 — Xanthangum — 0.1 Water 69.25 66.25

Manufacturing Process:

a) Polyethylene glycol and ethylene glycol palmitostearate, oleoylpolyoxyglycerides, and mineral oil are mixed and heated to about 50-70°C.

b) Propylparaben, methylparaben, and butylated hydroxytoluene are mixedwith the liquid of a) with continuous stirring at about 50-70° C.

c) Mometasone furoate is mixed with Transcutol P.

d) The material of (c) is mixed with the material of b).

e) Hydroxyethyl cellulose or xanthan gum is dissolved in water.

f) The oily phase of d) is added slowly to the aqueous phase of e), orvice versa, at about 50-70° C. with continuous stirring.

g) The mixture of f) is homogenized and allowed to cool to ambienttemperature.

Example 16 Dermal Toxicity Testing

A toxicity study is conducted, involving once-daily dermaladministration of 0.025 and 0.05% betamethasone dipropionate spraysprepared in Example 3 (Formulations C and D) at doses of 0.5 and 1mg/Kg/day for 28 days, to Sprague-Dawley rats. The formulations are welltolerated, as there is no severe or dose-limiting dermal irritation. Allanimals survive for the duration of the study and there are no testformulation-related clinical signs.

Systemic effects consist of decreased body weight gains and hematology,clinical chemistry and organ weight alterations at both doses of bothformulations. Many of these changes are consistent with thepharmacologic activity of the test drug, a synthetic corticosteroid.Decreases in lymphocytes and thymus and spleen weights, relative tocontrols, are consistent with the immunosuppresive effects of the drug.Increases in cholesterol in both sexes, and serum triglycerides infemales in all groups, appear to be associated with the glucocorticoidactivity of this drug. Decreases in adrenal weights are a known effectof corticosteroids. Histopathological changes consist of deceasedcellularity in the thymus, spleen, mesenteric, and mediastinal lymphnodes, as well as cortical atrophy in the adrenals, correlating with themacroscopic findings of small size. No remarkable differences betweendoses or betamethasone concentrations are noted. However, due to thedifferences in body weight of the treated animals in comparison tocontrols of approximately 10% or greater, resulting from decreased bodyweight gains, a “No Observed Adverse Effect Level” (NOAEL) cannot beestablished.

Example 17 Skin Permeation Testing

A skin permeation study is conducted using human skin, using the testprocedure described below. Samples of Formulations C, F, G, and K (fromExamples 2 and 3), and commercially available DIPROLENE lotion, aretested.

Franz diffusion cells, with an average surface area of approximately 0.6cm² and a volume of approximately 2 mL are used. Dermatomed human skinfrom three subjects is positioned between the donor and receivercompartments, such that for each test material there are three cells foreach donor, for each of the 8 and 24 hours test durations. The integrityof the dermatomed human skin is measured by electrical impedance. Theupper and lower donor chambers are filled with a PBS solution to allowfor current conductance across the skin. The skin samples showing animpedance of <2000 ohms are discarded and replaced. Followingmeasurement of skin impedance, the PBS solution is removed from thereceiver compartment and replaced with 200 μL of 2% Brij® 98v in PBS.The side arm and donor chamber are then both covered with Parafilm™prior to equilibrating in a water bath at 34-37° C. (to maintain a skinsurface temperature of 32±10° C.) for at least 30 minutes prior todosing. An additional Franz cell is also mounted but not dosed, and thetemperature at the surface of the skin is continuously monitored using atemperature probe to ensure the skin surface temperature remainsconstant at 32±10° C. throughout the experiment. The cells are dosedwith the test materials. After dosing, the upper donor chamber of theFranz cell is immediately replaced and secured. The Parafilm™ on theside arm is then removed and the receiver compartment is filled withpre-warmed receiver fluid. The Franz cell is then placed into apre-calibrated water bath, which maintains a skin surface temperature of32±10° C. The cells are left un-occluded for the duration of theexperiment. At time=0, 200 μL of the receiver fluid is removed with asyringe prior to dosing, and fresh pre-warmed receiver fluid is used toreplace the receiver fluid removed at this and each subsequent samplingtime point. At the end of each test duration, diluent is employed toremove and quantify residual betamethasone dipropionate from the surfaceof the skin and donor chamber individually. The betamethasonedipropionate is extracted from the stratum corneum. The viable epidermalmembrane and dermis layers of the skin are separated and thebetamethasone dipropionate is extracted from both layers. Drug presentin each layer is determined using HPLC.

Results of the skin permeation study are shown graphically in FIG. 2,where the “REF” bars are for DIPROLENE lotion. At 8 hours, the dermisdrug levels are generally higher or equal for formulations of theexamples, than levels for DIPROLENE lotion. Subcutaneous and epidermislevels are much lower for formulations of the examples than forDIPROLENE lotion. While it is not intended to be bound to any particulartheory, the higher dermis levels can translate into higher efficacy,while lower epidermis levels can translate into lower skin atrophypotential for formulations of the examples than for DIPROLENE lotion. Itis hypothesized that formulations of the examples allow the drug topenetrate skin more deeply, while the drug from DIPROLENE lotionpenetrates mainly into the epidermis.

At 24 hours, the fall in dermis levels is steeper for formulations ofthe examples, when compared to DIPROLENE lotion. Steeper rates of fallcan translate into lesser accumulation over multiple applications.Higher subcutaneous and epidermis levels for DIPROLENE lotion could becontributing to sustained dermis levels at 24 hours.

Dermis level variations may be due, to some extent, to formulationvariables such as different polymers, drug concentrations, and thediethyleneglycol monoethyl ether (“DEGME”) concentrations, and thesevariables are compiled in Table 6, where “HEC” is hydroxyethyl celluloseand “XG” is xanthan gum.

TABLE 6 Formulation Betamethasone DEGME Polymer C 0.05% 3% HEC F 0.025% 3% HEC G 0.05% 10%  HEC K 0.05% 3% XG DIPROLENE 0.05% — —

1.-35. (canceled)
 36. A propellant-free sprayable topical pharmaceuticalcomposition, comprising a steroid, an emulsifying agent, a polymer,water, a water-immiscible substance, and a penetration enhancer.
 37. Thecomposition according to claim 36, wherein the penetration enhancer inamounts about 0.001-15 percent by weight.
 38. The composition accordingto claim 36, wherein a steroid is selected from the group comprising ofalclometasone dipropionate, beclomethasone dipropionate, betamethasonedipropionate, betamethasone valerate, fluocinolone acetonide,halobetasol propionate, hydrocortisone aceponate, hydrocortisoneacetate, hydrocortisone valerate, hydrocortisone butyrate, mometasonefuroate, triamcinolone acetonide, clocortolone pivalate, clobetasolpropionate, desoximetasone, or fluticasone propionate.
 39. Thecomposition according to claim 36, wherein a penetration enhancer isselected from the group comprising of a polyol and esters, ethers,sulfoxides, fatty acids, fatty acid esters, or any combination thereof.40. The composition according to claim 39, wherein a penetrationenhancer is selected from the group comprising of polyethylene glycol,butanediol, polyethylene glycol monolaurate, diethylene glycol monoethylether, diethylene glycol monomethyl ether, dimethylsulfoxide,decylmethylsulfoxide, lauric acid, oleic acid, valeric acid, isopropylmyristate, isopropyl palmitate, methyl propionate, ethyl oleate, or anycombination thereof.
 41. The composition according to claim 36, whereina water-immiscible substance is selected from the group comprising ofvegetable oil, saturated paraffin oil, mineral oil, fatty acid, fattyester of a natural fatty acid, triglyceride of animal or vegetableorigin, medium chain triglyceride, mixture of mono-, di- and/ortri-glycerides, wax, hydrogenated vegetable oil, or any combinationthereof.
 42. The composition according to claim 36, wherein anemulsifying agent is selected from the group comprising of cationicsurfactant, anionic surfactant, zwitterionic surfactant, amphotericsurfactant, or any combination thereof.
 43. The composition according toclaim 42, wherein an emulsifying agent is selected from the groupcomprising of a sorbitan fatty acid ester, a mixture of partial estersof sorbitol and its mono- and di-anhydrides with fatty acids, apolyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate,cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acidester, or any combination thereof.
 44. The composition according toclaim 36, wherein a polymer is selected from the group comprising of,polyethylene glycol, acrylate polymer, methacrylate polymer,polyvinylpyrrolidone, copolymer based on butyl methacrylate and methylmethacrylate, vinyl acetate, polyvinyl acetate, cellulose, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthangum, tragacanth, guar gum, locust bean gum, acacia, alginate, celluloseacetate phthalate, cellulose acetate butyrate, hydroxypropylmethylcellulose phthalate, or any combination thereof.
 45. Thecomposition according to claim 36, is substantially free of either orboth of an alcohol and propylene glycol.
 46. The composition accordingto claim 36, is substantially non-foaming.
 47. The composition accordingto claim 36, is an aqueous-based emulsion.
 48. The composition accordingto claim 36, which, after spraying, does not form an occlusive film on asite of skin application.
 49. A propellant-free sprayable topicalpharmaceutical composition, comprising a betamethasone compound, inamounts equivalent to about 0.025 to about 0.1 percent by weight ofbetamethasone base, an emulsifying agent, a polymer, water, awater-immiscible substance, and a penetration enhancer.
 50. Thecomposition of claim 49, wherein penetration enhancer in amounts about0.001 to about 15 percent by weight.
 51. The composition of claim 49,wherein a betamethasone compound is betamethasone benzoate,betamethasone dipropionate, betamethasone sodium phosphate, orbetamethasone valerate.
 52. The composition according to claim 36, fortreating one or more of atopic dermatitis, seborrhoeic dermatitis,eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of thescalp, steroid responsive dermatoses, erythema, or contact sensitivityreactions, and other associated diseases or disorders.
 53. Thecomposition according to claim 49, for treating one or more of atopicdermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis,erythroderma psoriasis, and psoriasis of the scalp, steroid responsivedermatoses, erythema, or contact sensitivity reactions, and otherassociated diseases or disorders.